Background: Concurrent with the opioid overdose crisis there has been an increase in hospitalizations among people with opioid use disorder (OUD), with one in ten hospitalized medical or surgical patients having comorbid opioid-related diagnoses. We sought to conduct a systematic review of hospital-based interventions, their staffing composition, and their impact on outcomes for patients with OUD hospitalized for medical or surgical conditions. Methods: Authors searched PubMed MEDLINE, PsychINFO, and CINAHL from January 2015 through October 2020. The authors screened 463 titles and abstracts for inclusion and reviewed 96 full-text studies. Seventeen articles met inclusion criteria. Extracted were study characteristics, outcomes, and intervention components. Methodological quality was evaluated using the Methodological Quality Rating Scale. Results: Ten of the 17 included studies were controlled retrospective cohort studies, five were uncontrolled retrospective studies, one was a prospective quasi-experimental evaluation, and one was a secondary analysis of a completed randomized clinical trial. Intervention components and outcomes varied across studies. Outcomes included in-hospital initiation and post-discharge connection to medication for OUD, healthcare utilization, and discharge against medical advice. Results were mixed regarding the impact of existing interventions on outcomes. Most studies focused on linkage to medication for OUD during hospitalization and connection to post-discharge OUD care. Conclusions: Given that many individuals with OUD require hospitalization, there is a need for OUD-related interventions for this patient population. Interventions with the best evidence of efficacy facilitated connection to post-discharge OUD care and employed an Addiction Medicine Consult model.
WeissAJ, ElixhauserA, BarrettML Opioid-related inpatient stays and emergency department visits by state, 2009–2014: statistical brief# 219. 2017.
2.
HoltSR, RamosJ, HarmaMAPrevalence of unhealthy substance use on teaching and hospitalist medical services: implications for education. Am J Addict. 2012;21(2):111–119.
3.
McNeelyJ, GourevitchMN, PaoneDEstimating the prevalence of illicit opioid use in New York City using multiple data sources. BMC Public Health. 2012;12(1):443.
4.
BlanchardJ, WeissAJ, BarrettMLReadmissions following inpatient treatment for opioid-related conditions. Subst Use Misuse. 2019;54(3):473–481.
5.
DewanKC, DewanKS, IdreesJJTrends and outcomes of cardiovascular surgery in patients with opioid use disorders. JAMA Surg. 2019;154(3):232–240.
6.
LarochelleMR, BernsonD, LandTMedication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
7.
SimonR, SnowR, WakemanS.Understanding why patients with substance use disorders leave the hospital against medical advice: a qualitative study. Subst Abus. 2020;41(4):519–525.
8.
StrangJ, VolkowND, DegenhardtLOpioid use disorder. Nat Rev Dis Primers. 2020;6(1):1–28.
9.
VolkowND.Medications for opioid use disorder: bridging the gap in care. The Lancet. 2018;391(10118):285–287.
10.
AllenB, NolanML, PaoneD.Underutilization of medications to treat opioid use disorder: what role does stigma play?Subst Abus. 2019;40(4):459–465.
11.
MadrasBK, AhmadNJ, WenJ, SharfsteinJ.Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspectives. 2020. https://doi.org/10.31478/202004b
12.
GoedelWC, ShapiroA, CerdáMAssociation of racial/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States. JAMA Netw Open. 2020;3(4):e203711.
13.
BhatrajuEP, Ludwig-BarronN, Takagi-StewartJSuccessful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma. Drug Alcohol Depend. 2020;215:108253.
14.
PriestKC, McCartyD.The role of the hospital in the 21st century opioid overdose epidemic: the Addiction Medicine Consult Service. J Addict Med. 2019;13(2):104–112.
15.
MarksLR, MunigalaS, WarrenDKAddiction medicine consultations reduce readmission rates for patients with serious infections from opioid use disorder. Clin Infect Dis. 2019;68(11):1935–1937.
16.
TangVM, Lam-Shang-LeenJ, BrothersTDCase series: limited opioid withdrawal with use of transdermal buprenorphine to bridge to sublingual buprenorphine in hospitalized patients. Am J Addict. 2020;29(1):73–76.
17.
EnglanderH, DobbertinK, LindBKInpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis. J Gen Intern Med. 2019;34(12):2796–2803.
18.
NordeckCD, WelshC, SchwartzRPRehospitalization and substance use disorder (SUD) treatment entry among patients seen by a hospital SUD consultation-liaison service. Drug Alcohol Depend. 2018;186:23–28.
WakemanSE, MetlayJP, ChangY, HermanGE, RigottiNA.Inpatient addiction consultation for hospitalized patients increases post-discharge abstinence and reduces addiction severity. J Gen Intern Med. 2017;32(8):909–916.
21.
WeinsteinZM, ChengDM, D'AmicoMJInpatient addiction consultation and post-discharge 30-day acute care utilization. Drug Alcohol Depend. 2020;213:108081.
22.
SuzukiJ, DeVidoJ, KalraIInitiating buprenorphine treatment for hospitalized patients with opioid dependence: a case series. Am J Addict. 2015;24(1):10–14.
23.
PatelRS, ManikkaraG, PatelP, TalukdarJ, MansuriZ.Importance of behavioral therapy in patients hospitalized for post-traumatic stress disorder (PTSD) with opioid use disorder. Behav Sci. 2018;8(8):73.
24.
PriestKC, LovejoyTI, EnglanderH, ShullS, McCartyD.Opioid agonist therapy during hospitalization within the veterans health administration: a pragmatic retrospective cohort analysis. J Gen Intern Med. 2020;35(8):2365–2374.
25.
WangSJ, WadeE, TowleJEffect of inpatient medication-assisted therapy on against-medical-advice discharge and readmission rates. Am J Med. 2020;133(11):1343–1349.
26.
RayV, WaiteMR, SpexarthFCAddiction management in hospitalized patients with intravenous drug use-associated infective endocarditis. Psychosomatics. 2020;61(6):678–687.
27.
ThompsonHM, HillK, JadhavRThe substance use intervention team: a preliminary analysis of a population-level strategy to address the opioid crisis at an academic health center. J Addict Med. 2019;13(6):460–463.
28.
Substance Abuse Mental Health Services Administration. Federal guidelines for opioid treatment programs. Rockville (MD): SAMHSA; 2015.
29.
ApodacaTR, MillerWR.A meta-analysis of the effectiveness of bibliotherapy for alcohol problems. J Clin Psychol. 2003;59(3):289–304.
30.
VaughnMG, HowardMO.Adolescent substance abuse treatment: a synthesis of controlled evaluations. Res Social Work Pract. 2004;14(5):325–335.
31.
LiW, HowardMO, GarlandEL, McGovernP, LazarM.Mindfulness treatment for substance misuse: a systematic review and meta-analysis. J Subst Abuse Treat. 2017;75:62–96.
32.
BrarR, FairbairnN, ColizzaK, RyanA, NolanS.Hospital initiated injectable opioid agonist therapy for the treatment of severe opioid use disorder: a case series. J Addict Med. 2021;15(2):163–166.
33.
SuzukiJ.Medication-assisted treatment for hospitalized patients with intravenous-drug-use related infective endocarditis. Am J Addict. 2016;25(3):191–194.
34.
CushmanPA, LiebschutzJM, AndersonBJ, MoreauMR, SteinMD.Buprenorphine initiation and linkage to outpatient buprenorphine do not reduce frequency of injection opiate use following hospitalization. J Subst Abuse Treat. 2016;68:68–73.
35.
MeyersonBE, RussellDM, KichlerMI don't even want to go to the doctor when I get sick now: healthcare experiences and discrimination reported by people who use drugs, Arizona 2019. Int J Drug Policy. 2021;93:103112.
36.
Theisen-ToupalJ, RonanMV, MooreA, RosenthalES.Inpatient management of opioid use disorder: a review for hospitalists. J Hosp Med. 2017;12(5):369–374.
37.
SuzukiJ, RobinsonD, MosqueraMImpact of medications for opioid use disorder on discharge against medical advice among people who inject drugs hospitalized for infective endocarditis. Am J Addict. 2020;29(2):155–159.
KilaruAS, XiongA, LowensteinMIncidence of treatment for opioid use disorder following nonfatal overdose in commercially insured patients. JAMA Netw Open. 2020;3(5):e205852.
41.
KrawczykN, FederKA, FingerhoodMI, SalonerB.Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a US national sample. Drug Alcohol Depend. 2017;178:512–518.
